OR WAIT null SECS
Nanoform and Boehringer Ingelheim have executed a master services agreement in relation to pre-clinical development projects.
Nanoparticle medicine enabling company, Nanoform, and research-driven pharma company, Boehringer Ingelheim, have executed a master services agreement in relation to pre-clinical development projects.
Through the agreement, which was announced in an Aug. 3, 2021 press release, the companies will work together to try and solve the growing challenge of poor bioavailability and solubility in new drug candidates. As per the partnership, Boehringer Ingelheim will be able to perform proof of concept studies to assess the added value of Nanoform’s Controlled Expansion of Supercritical Solutions (CESS) technology to drug development projects.
“Wider uptake of the latest technological innovations is essential to address the low success rates for new drug candidates in Pharma,” said Christian Jones, CCO of Nanoform, in the press release. “We are delighted to collaborate with Boehringer Ingelheim to evaluate how our proprietary CESS platform can help more novel therapies reach the patients who need them. This is the first step toward what we hope will be a long and fruitful partnership between our companies.”